×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Caribou Biosciences Inc. (CRBU) NASDAQ

$5.14 0.02 (0.39%)

Market Cap: $464.22M

As of 03/28/24 04:00 PM EDT. Market closed.

(CRBU)

Caribou Biosciences Inc. (CRBU)
NASDAQ

$5.14
0.02 (0.39%)

Market Cap: $464.22M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or ... read more

caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever"? and the new york times has noted that "the pace of new discoveries and applications is dizzying."? caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
PRICE CHART FOR CARIBOU BIOSCIENCES INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$5.17
Previous Close
$5.12
Days Range
$5.07 - $5.23
52 week range
$3.44 - $8.59
Volume
1,347,717
Avg. Volume (30 days)
1,809,404
Market Cap
$464.22M
Dividend Yield
-
P/E
(4.55)
Shares Outstanding
90,314,501
Open
$5.17
Previous Close
$5.12
Days Range
$5.07 - $5.23
52 week range
$3.44 - $8.59
Volume
1,347,717
Avg. Volume (30 days)
1,809,404
Market Cap
$464.22M
Dividend Yield
-
P/E
(4.55)
Shares Outstanding
90,314,501
FINANCIAL STATEMENTS FOR CARIBOU BIOSCIENCES INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR CARIBOU BIOSCIENCES INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Kanner StevenChief Scientific OfficerFeb 06, 2024 Option Exercise$2.6930,57782,252354,037Feb 08, 2024, 05:06 PM
Haurwitz Rachel E.President and CEOJun 08, 2023 Option Exercise$2.9610,00029,60040,000Jun 09, 2023, 04:31 PM
Haurwitz Rachel E.President and CEOMar 20, 2023 Option Exercise$2.9610,00029,60030,000Mar 22, 2023, 04:16 PM
Rizvi Syed Ali-aamirChief Medical OfficerJan 19, 2023 Sale$6.315,62735,50659,373Jan 20, 2023, 04:13 PM
Kanner StevenChief Scientific OfficerDec 02, 2022 Option Exercise$2.6921,40157,569323,460Dec 02, 2022, 07:01 PM
Fischesser RyanVP of Finance and ControllerOct 06, 2022 Option Exercise$3.405,67819,305116,044Oct 07, 2022, 05:13 PM
Fischesser RyanVP of Finance and ControllerOct 06, 2022 Sale$10.8010,000107,958110,366Oct 07, 2022, 05:13 PM
MCCLUNG BARBARA GChief Legal OfficerSep 15, 2022 Option Exercise$2.6927,59574,231376,566Sep 16, 2022, 04:14 PM
Kanner StevenChief Scientific OfficerAug 25, 2022 Option Exercise$2.6943,248116,337345,307Aug 26, 2022, 05:42 PM
Kanner StevenChief Scientific OfficerAug 25, 2022 Sale$11.2243,248485,221302,059Aug 26, 2022, 05:42 PM
Kanner StevenChief Scientific OfficerMay 13, 2022 Option Exercise$1.8874,420140,081302,059May 17, 2022, 08:51 PM
Haurwitz Rachel E.President and CEOMay 09, 2022 Option Exercise$2.9610,00029,60020,000May 10, 2022, 07:32 PM
Haurwitz Rachel E.President and CEOJan 26, 2022 Option Exercise$2.9610,00029,60010,000May 10, 2022, 07:29 PM
Fischesser RyanVP of Finance and ControllerMay 05, 2022 Option Exercise$3.402,2747,733115,518May 06, 2022, 07:28 PM
Fischesser RyanVP of Finance and ControllerMar 15, 2022 Option Exercise$3.402,2747,733113,244Mar 17, 2022, 07:14 PM
Kanner StevenChief Scientific OfficerMar 04, 2022 Option Exercise$2.9010,72031,036227,639Mar 07, 2022, 07:58 PM
O'Byrne JasonChief Financial OfficerFeb 08, 2022 Option Exercise$4.1124,336100,02124,336Feb 08, 2022, 07:27 PM
Haurwitz Rachel E.President and CEOJan 26, 2022 Option Exercise$2.9610,00029,6003,359,395Jan 27, 2022, 04:41 PM
Fischesser RyanVP of Finance and ControllerJan 11, 2022 Buy$4.007,38729,553109,082Jan 12, 2022, 04:35 PM
Fischesser RyanVP of Finance and ControllerDec 20, 2021 Buy$2.691,1363,056101,695Dec 21, 2021, 05:23 PM
MCCLUNG BARBARA GChief Legal OfficerDec 07, 2021 Buy$2.696,12716,482348,971Dec 08, 2021, 06:06 PM
MCCLUNG BARBARA GChief Legal OfficerOct 20, 2021 Buy$2.699,21924,799342,844Oct 21, 2021, 06:12 PM
Kanner StevenChief Scientific OfficerOct 12, 2021 Buy$1.92114,860220,757215,031Oct 13, 2021, 07:31 PM
Fischesser RyanVP of Finance and ControllerOct 11, 2021 Buy$2.691,7464,697100,559Oct 12, 2021, 07:33 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Kanner StevenChief Scientific Officer02/06/202482,252
Haurwitz Rachel E.President and CEO06/08/202329,600
Haurwitz Rachel E.President and CEO03/20/202329,600
Rizvi Syed Ali-aamirChief Medical Officer01/19/202335,506
Kanner StevenChief Scientific Officer12/02/202257,569
Fischesser RyanVP of Finance and Controller10/06/202219,305
Fischesser RyanVP of Finance and Controller10/06/2022107,958
MCCLUNG BARBARA GChief Legal Officer09/15/202274,231
Kanner StevenChief Scientific Officer08/25/2022116,337
Kanner StevenChief Scientific Officer08/25/2022485,221
Kanner StevenChief Scientific Officer05/13/2022140,081
Haurwitz Rachel E.President and CEO05/09/202229,600
Haurwitz Rachel E.President and CEO01/26/202229,600
Fischesser RyanVP of Finance and Controller05/05/20227,733
Fischesser RyanVP of Finance and Controller03/15/20227,733
Kanner StevenChief Scientific Officer03/04/202231,036
O'Byrne JasonChief Financial Officer02/08/2022100,021
Haurwitz Rachel E.President and CEO01/26/202229,600
Fischesser RyanVP of Finance and Controller01/11/202229,553
Fischesser RyanVP of Finance and Controller12/20/20213,056
MCCLUNG BARBARA GChief Legal Officer12/07/202116,482
MCCLUNG BARBARA GChief Legal Officer10/20/202124,799
Kanner StevenChief Scientific Officer10/12/2021220,757
Fischesser RyanVP of Finance and Controller10/11/20214,697
Load More Insider Transactions
FUNDS WITH A POSITION IN CARIBOU BIOSCIENCES INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.7,068,4680.00103%16.17%Other
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)3,500,0000.37%ExitedOther
GEODE CAPITAL MANAGEMENT, LLC1,794,6480.00108%13.79%Other
CANDRIAM S.C.A.860,0240.03%NewOther
MAVERICK CAPITAL LTD652,5420.08%No changeGrowth At A Reasonable Price, Growth
ADAGE CAPITAL PARTNERS GP, L.L.C.203,9330.00242%-19.69%Other
ROYCE & ASSOCIATES LP253,1020.01%940.93%Value
BRUCE & CO., INC.200,0000.4%No changeValue
RENAISSANCE TECHNOLOGIES LLC32,4000.00029%NewOther
PENTWATER CAPITAL MANAGEMENT LP10,000 (Call)0.00026%ExitedEvent Driven
CHANGE IN SHARES OUTSTANDING FOR CARIBOU BIOSCIENCES INC
STOCK BUYBACKS FOR CARIBOU BIOSCIENCES INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
-11.91%
1Q
12/31/2023
06/30/2023
20.17%
2Q
12/31/2023
03/31/2023
20.63%
3Q
12/31/2023
12/31/2022
20.98%
4Q
12/31/2023
09/30/2022
21.22%
5Q
12/31/2023
06/30/2022
21.48%
6Q
12/31/2023
03/31/2022
21.90%
7Q
12/31/2023
09/30/2021
60.84%
9Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
-11.91%
1Q
06/30/2023
20.17%
2Q
03/31/2023
20.63%
3Q
12/31/2022
20.98%
4Q
09/30/2022
21.22%
5Q
06/30/2022
21.48%
6Q
03/31/2022
21.90%
7Q
09/30/2021
60.84%
9Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CARIBOU BIOSCIENCES INC
LOADING...